-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1342 Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Program: Oral and Poster Abstracts
Session: 605. Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster I
Hematology Disease Topics & Pathways:
Research, Antibody Therapy, Biological therapies, non-Hodgkin lymphoma, Lymphomas, B Cell lymphoma, drug development, Diseases, Immunotherapy, Therapies, Lymphoid Malignancies
Saturday, December 10, 2022, 5:30 PM-7:30 PM

Anna Kuchnio, PhD1, Danlin Yang, PhD2*, Nele Vloemans1*, Cassandra Lowenstein2*, Ivo Cornelissen1*, Ricardo Amorim, PhD1*, Chao Han2*, Siddharth Sukumaran, PhD2*, Lut Janssen1*, Toon Suls1*, Mariette Bekkers1*, Elena Lasorsa, PhD1*, Lorena Fontana, PhD1*, Nicole Medeiros2*, Bingyuan Wu, PhD2*, Jun Chen2*, Michael Feldkamp, PhD2*, Sheng-Jiun Wu2*, Habtom Habte, PhD2*, John Krayer2*, Cam Holland2*, M. Phillip Deyoung, PhD2, Yusri A Elsayed, MD, PhD2* and Ulrike Philippar, PhD1

1Janssen Research & Development, Beerse, Belgium
2Janssen Research & Development, Spring House, PA

Background: B-cell non-Hodgkin lymphoma (B-NHL) is the most common hematological malignancy worldwide. Despite improvements in available therapies, relapsed/refractory (R/R) B-NHLs are characterized by poor prognosis. Immunotherapies engaging T cells, such as chimeric antigen receptor T cells (CAR-T) or bispecific cluster of differentiation (CD)3 redirection antibodies, show promising response rates in the clinic. T-cell redirection using antibodies that recognize CD3 on T cells and specific antigens on malignant cells is a novel treatment modality that may help patients whose disease no longer responds to prior lines of therapy. To further increase the efficacy of CD3 redirection therapies in B-NHL, we designed a trispecific antibody targeting two tumor antigens. CD79b and CD20 are well-validated therapeutic targets with their expression restricted to the B cell lineage and expressed in most B‑cell malignancies, making them ideal T-cell redirection targets. Dual antigen recognition on B-NHL cells with a trispecific T‑cell redirecting antibody has the potential to enhance tumor binding through avidity effects, maximize tumor eradication in the presence of a heterogeneous cell population, and prevent resistance via tumor antigen escape.

Methods: JNJ-80948543 is a fully human immunoglobulin G1 trispecific antibody composed of an anti-CD3ɛ single-chain variable fragment (scFv), an anti-CD20 scFv, and an anti-CD79b fragment antigen-binding (Fab) domain and an effector-silent Fc. It was selected based on biophysical assessment, low-affinity CD3 engagement, and observed therapeutic efficacy in multiple lymphoma models.

Results: JNJ-80948543 demonstrated high affinity and stable binding over 48 hours in lymphoma cells expressing varying endogenous CD79b and CD20 receptor densities. In contrast, low-affinity binding to primary human T cells expressing CD3 was observed. In vitro, JNJ-80948543 cytotoxicity was observed in a broad panel of lymphoma cells and in primary B cells. T-cell activation was observed with low cytokine secretion. Moreover, JNJ-80948543 mediated cytotoxicity of single target expressing tumor cells (CD79b or CD20) but demonstrated >1,000-fold greater potency towards cells expressing both CD79b and CD20, consistent with an avidity effect. Importantly, there was no impact on target cell viability or T cell activation in co-culture with antigen-negative cells. In vivo, JNJ-80948543 prevented the growth of CARNAVAL (GCB-DLBCL) xenografts and induced dose-dependent regression of OCI-Ly10 (ABC-DLBCL) xenograft tumors.

Conclusions: Taken together, JNJ-80948543 is a potential first-in-class trispecific antibody for the treatment of B‑NHL malignancies with high unmet medical needs. A Phase I dose-escalation study of JNJ-80948543 in patients with relapsed/refractory Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia (CLL) will be initiated.

Disclosures: Kuchnio: Janssen: Current Employment. Yang: Janssen: Ended employment in the past 24 months. Vloemans: Janssen: Current Employment. Lowenstein: Janssen: Ended employment in the past 24 months. Cornelissen: Janssen: Current Employment. Amorim: Janssen: Current Employment. Han: Janssen: Ended employment in the past 24 months. Sukumaran: Janssen: Current Employment. Janssen: Janssen: Current Employment. Suls: Janssen: Current Employment. Bekkers: janssen: Current Employment. Lasorsa: Janssen: Current Employment. Fontana: Janssen: Current Employment. Medeiros: Janssen: Current Employment. Wu: Janssen: Current Employment. Chen: Janssen: Current Employment. Feldkamp: Janssen: Current Employment. Wu: Janssen: Current Employment. Habte: Janssen: Current Employment. Krayer: Janssen: Consultancy. Holland: Janssen: Current Employment. Deyoung: Janssen: Current Employment. Elsayed: Janssen: Current Employment. Philippar: Janssen: Current Employment.

*signifies non-member of ASH